Stem Cell Marker Aldehyde Dehydrogenase 1A1 Expression in Triple-negative Breast Carcinoma

Marwa Abdel Nasser Mohamed; Badawia Bayoumi Ibrahim; Samar Abdel Monem El Sheikh; Mona Salah Abdel Magid

doi:10.3889/oamjms.2022.8439

Authors

Marwa Abdel Nasser Mohamed Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Badawia Bayoumi Ibrahim Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Samar Abdel Monem El Sheikh Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Mona Salah Abdel Magid Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2022.8439

Keywords:

Cancer stem cells, Aldehyde dehydrogenase 1A1, Triple negative breast cancer

Abstract

Background: Increasing evidence has proposed that tumor contains tumor initiating cells or cancer stem cells (CSCs) are responsible for its progression and relapse. Aldehyde dehydrogenase 1A1 (ALDH1A1) has recently been identified as a marker for cancer stem cells in some human malignancies including breast cancer.Triple negative breast carcinomas (TNBCs) are group of primary breast tumors with aggressive clinical behavior that have no targeted therapy at present.

Aim: The assessment of immunohistochemical expression of ALDH1A1 in triple negative breast carcinoma and its correlation with the clinicopathological features of TNBC.

Material and Methods: This study consisted of 60 cases of TNBC. Immunohistochemical reactions were carried out by using ALDH1A1 monoclonal antibody. A total score of ALDH1A1 expression is obtained by multiplying the score of staining intensity & percentage of stained cells to obtain score ranging from 0 up to 300. Due to the relatively large number of positive cases, a statistical analysis
was performed with a negative (score ≤ 10) and positive (score > 10) cutoff [1].

Results: Evaluation of the results of immunostaining for ALDH1A1 showed 88.3% of totalcases (53 cases) having a positive cytoplasmic reactivity. Statistical analysis for a possible correlation between ALDH1A1 expression and prognostic clinicopathological parameters; age, size, tumor grade, histologic subtypes, lymphovascular invasion, intraductal components, tumor infiltrating lymphocytes and TNM stage grouping revealed a non-significant correlation.

Conclusion: ALDH1A1 couldn’t be used solely as a diagnostic or prognostic marker In TNBCs. Further research combining with other biomarkers and with a greater number of patients is necessary to confirm the role of ALDH1A1 in TNBC.

Key words: Cancer stem cells (CSCs), Aldehyde dehydrogenase 1A1 (ALDH1A1), Triple Negative Breast cancer (TNBC).

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Ma F, Li H, Li Y, Ding X, Wang H, Fan Y, et al. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC). Medicine (Baltimore). 2017;96(14):e6561. https://doi.org/10.1097/MD.0000000000006561 PMid:28383433 DOI: https://doi.org/10.1097/MD.0000000000006561

Butti R, Gunasekaran VP, Kumar TV, Banerjee P, Kundu GC. Breast cancer stem cells: Biology and therapeutic implications. Int J Biochem Cell Biol. 2019;107:38-52. https://doi.org/10.1016/j.biocel.2018.12.001 PMid:30529656 DOI: https://doi.org/10.1016/j.biocel.2018.12.001

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674-90. https://doi.org/10.1038/nrclinonc.2016.66 PMid:27184417 DOI: https://doi.org/10.1038/nrclinonc.2016.66

Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24 Suppl 2:S26-35. https://doi.org/10.1016/j.breast.2015.07.008 PMid:26253814 DOI: https://doi.org/10.1016/j.breast.2015.07.008

Pires BR, De Amorim IS, Souza LD, Rodrigues JA, Mencalha AL. Targeting cellular signaling pathways in breast cancer stem cells and its implication for cancer treatment. Anticancer Res. 2016;36(11):5681-91. https://doi.org/10.21873/anticanres.11151 PMid:27793889 DOI: https://doi.org/10.21873/anticanres.11151

Vassalli G. Aldehyde dehydrogenases: Not just markers, but functional regulators of stem cells. Stem Cells Int. 2019;2019;3904645. https://doi.org/10.1155/2019/3904645 PMid:30733805 DOI: https://doi.org/10.1155/2019/3904645

Martinez-Cruzado L, Tornin J, Santos L, Rodriguez A, García- Castro J, Morís F, et al. Aldh1 expression and activity increase during tumor evolution in sarcoma cancer stem cell populations. Sci Rep. 2016;6:27878. https://doi.org/10.1038/srep27878 PMid:27292183 DOI: https://doi.org/10.1038/srep27878

Yang W, Wang Y, Wang W, Chen Z, Bai G. Expression of aldehyde dehydrogenase 1A1 (ALDH1A1) as a prognostic biomarker in colorectal cancer using immunohistochemistry. Med Sci Monit. 2018;24:2864-72. https://doi.org/10.12659/MSM.910109 PMid:29748529 DOI: https://doi.org/10.12659/MSM.910109

Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181-5. https://doi.org/10.1111/his.14091 PMid:32056259 DOI: https://doi.org/10.1111/his.14091

Mei F, Liu JY, Xue WC. Histopathological grading of invasive breast carcinoma: Nottingham histopathological grading system. Chin J Pathol. 2019;48(8):659-64.

Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: Breast cancer. Ann Surg Oncol. 2018;25(7):1783-5. https://doi.org/10.1245/s10434-018-6486-6 PMid:29671136 DOI: https://doi.org/10.1245/s10434-018-6486-6

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48-72. https://doi.org/10.5858/134.7.e48 PMid:20586616 DOI: https://doi.org/10.5858/134.7.e48

Wolff AC, Hammond ME, Hayes DF. Re: Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst. 2012;104(12):957-8. https://doi.org/10.1093/jnci/djs243 PMid:22581974 DOI: https://doi.org/10.1093/jnci/djs243

Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol. 2002;161(4):1223-33. https://doi.org/10.1016/S0002-9440(10)64399-4 PMid:12368196 DOI: https://doi.org/10.1016/S0002-9440(10)64399-4

Rakha E, El-Sayed M, Green A, Lee A, Robertson JF, Ellis IO. Prognostic markers in triple negative breast cancer. Cancer. 2007;109(1):25-32. https://doi.org/10.1002/cncr.22381 PMid:17146782 DOI: https://doi.org/10.1002/cncr.22381

Rebecca D, Maureen T, Kathleen P, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429-34. https://doi.org/10.1158/1078-0432.CCR-06-3045 PMid:17671126 DOI: https://doi.org/10.1158/1078-0432.CCR-06-3045

Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH. Triple negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010;23(1):123-33. https://doi.org/10.1038/modpathol.2009.145 PMid:19855377 DOI: https://doi.org/10.1038/modpathol.2009.145

Nassar A, Sookhan N, Santisteban M, Bryant SC, Boughey JC, Giorgadze T, et al. Diagnostic utility of snail in metaplastic breast carcinoma. Diagn Pathol. 2010;5:76. https://doi.org/10.1186/1746-1596-5-76 PMid:21110878 DOI: https://doi.org/10.1186/1746-1596-5-76

Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, et al. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: A clinical study of triple-negative breast carcinomas. PLoS One. 2012;7(9):e45831. https://doi.org/10.1371/journal.pone.0045831 PMid:23049873 DOI: https://doi.org/10.1371/journal.pone.0045831

Hegmane A, Liepniece-Karele I. Response to neoadjuvant therapy and long-term outcome in patients with triple negative breast cancer. Eur Sci J. 2014;10(12):1857-7881.

Ishikawa Y, Horiguchi J, Toya H, Nakajima H, Hayashi M, Tagaya N, et al. Triple-negative breast cancer: Histological subtypes and immunohistochemical and clinicopathological features. Sci J. 2011;102(3):656-62. https://doi.org/10.1111/j.1349-7006.2011.01858 DOI: https://doi.org/10.1111/j.1349-7006.2011.01858.x

Disis ML and Stanton SE. Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm. Virginia, United States: ASCO Educational Book; 2015. DOI: https://doi.org/10.14694/EdBook_AM.2015.35.e25

Pruneri G, Vingiani A, Bagnardi V, Rotmensz N, De Rose A, Palazzo A, et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple negative breast cancer. Ann Oncol. Ann Oncol. 2016;27(2):249-56. https://doi.org/10.1093/annonc/mdv571 PMid:26598540 DOI: https://doi.org/10.1093/annonc/mdv571

Agarwal G, Nanda G, Lal P, Mishra A, Agarwal A, Agrawal V, et al. Outcomes of triple-negative breast cancers (TNBC) compared with non-TNBC: Does the survival vary for all stages? World J Surg. 2016;40(6):1362-72. https://doi.org/10.1007/s00268-016-3422-4 PMid:26842691 DOI: https://doi.org/10.1007/s00268-016-3422-4

Yuan N, Meng M, Liu C, Feng L, Hou L, Ning Q, et al. Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol. 2014;2(2):245-51. https://doi.org/10.3892/mco.2013.230 PMid:24649341 DOI: https://doi.org/10.3892/mco.2013.230

Atwa HA, Ibrahim HM, Ismail EI, Ibrahim IM. ALDH 1A1 and caveolin-1 expression in triple negative breast cancer. Oncol Transl Med. 2017;3:185-96. https://doi.org/10.1007/s10330-017-0231-1 DOI: https://doi.org/10.9734/JPRI/2017/36948

Murrja E, Turna ZH, Ozturk MA, Cinkaya A, Ozturk T. Aldehyde dehydrogenase-1 expression and prognosis in triple-negative breast cancer. Med Sci Discov. 2014;1(2):44. https://doi.org/10.17546/msd.82203 DOI: https://doi.org/10.17546/msd.82203

Kunju LP, Cookingham C, Toy KA, Chen W, Sabel MS, Kleer CG. EZH2 and ALDH-1-mark breast epithelium at risk for breast cancer development. Mod Pathol. 2011;24(6):786-93. https://doi.org/10.1038/modpathol.2011.8. PMid:21399615 DOI: https://doi.org/10.1038/modpathol.2011.8

Madjd Z, Ramezani B, Molanae S, Asadi-Lari M. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev. 2012;13(6):2973-8. https://doi.org/10.7314/apjcp.2012.13.6.2973 PMid:22938492 DOI: https://doi.org/10.7314/APJCP.2012.13.6.2973

Ma F, Li H, Wang H, Shi X, Fan Y, Ding X, et al. Enriched CD44+/CD24-population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett. 2014;353(2):153-9. https://doi.org/10.1016/j.canlet.2014.06.022 PMid:25130168 DOI: https://doi.org/10.1016/j.canlet.2014.06.022

Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, et al. Prognostic impact of ALDH1 in breast cancer: A story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2010;123(1):97-108. https://doi.org/10.1007/s10549-009-0619-3 PMid:19911270 DOI: https://doi.org/10.1007/s10549-009-0619-3

Hosni H, Daoud S, Bassam A. Immunohistochemical study of stem cell marker ALDH 1A1 and BRCA1 in breast cancer. Acad J Cancer Res 2014;7:1-7. DOI: https://doi.org/10.1016/j.ejca.2014.03.033

Li H, Ma F, Wang H, Lin C, Fan Y, Zhang X, et al. Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer. Int J Biol Markers. 2013;28(4):e357-64. https://doi.org/10.5301/jbm.5000048 PMid:24338721 DOI: https://doi.org/10.5301/JBM.5000048

Ohi Y, Umekita Y, Yoshioka T, Souda M, Rai Y, Sagara Y, et al. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology. 2011;59(4):776-80. https://doi.org/10.1111/j.1365-2559.2011.03884.x PMid:22014057 DOI: https://doi.org/10.1111/j.1365-2559.2011.03884.x

Kurbel S. In search of triple-negative DCIS: Tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol. 2013;34(1):1-7. https://doi.org/10.1007/s13277-012-0602-1 PMid:23208673 DOI: https://doi.org/10.1007/s13277-012-0602-1

Khoury T, Ademuyiwa FO, Chandrasekhar R, Jabbour M, Deleo A, Ferrone S, et al. Aldehyde dehdrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol. 2012;25(3):388-97. https://doi.org/10.1038/modpathol.2011.172 PMid:22080062 DOI: https://doi.org/10.1038/modpathol.2011.172

Liu Y, Lv DL, Duan JJ, Xu SL, Zhang JF, Yang XJ, et al. ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: A systematic review and meta-analysis. BMC Cancer. 2014;14:444. https://doi.org/10.1186/1471-2407-14-444 PMid:24938375 DOI: https://doi.org/10.1186/1471-2407-14-444